Tilray IPO

Background: Privateer, Nanaimo, and the road to Nasdaq

Tilray was incorporated as a subsidiary of Privateer Holdings, a Seattle-based private equity firm founded in 2010 by Brendan Kennedy, Christian Groh, and Michael Blue. Privateer had built a portfolio that included Leafly and the Marley Natural brand before turning Tilray into its flagship cultivator ^[1][2].

Tilray received one of Canada's earliest commercial cultivation licenses under the Marihuana for Medical Purposes Regulations (MMPR), and opened a 60,000-square-foot facility in Nanaimo, British Columbia in 2014 ^[3]. By 2018, with the Cannabis Act on track to legalize adult-use cannabis in Canada that October, Canadian producers were racing to raise capital. Most listed on the Toronto Stock Exchange or the TSX Venture Exchange. Tilray chose a different path: a direct IPO on the Nasdaq Global Select Market in the United States ^[1].

The IPO: July 19, 2018

Tilray priced 9,000,000 Class 2 common shares at US$17.00 on July 18, 2018, the top of its $14–$16 marketed range, and began trading on Nasdaq under the symbol TLRY on July 19, 2018 ^[1][4]. Gross proceeds were approximately US$153 million before the underwriters' overallotment option. Cowen and Company and BMO Capital Markets led the offering.

What made the listing historically significant was venue, not size. Other large producers — Canopy Growth, Aurora Cannabis, Aphria — were either listed only in Canada or traded in the US over-the-counter. Tilray became the first company whose primary business was growing and selling cannabis to complete a traditional IPO on a major US exchange ^[4][5]. Shares closed their first day at $22.39, up roughly 32% ^[4].

The public float was unusually small. Privateer Holdings retained approximately 75 million of the roughly 93 million shares outstanding, and those shares were locked up for 180 days ^[1]. Only about 17–18 million shares were actually available to trade.

The September 2018 squeeze

Between July and mid-September 2018, TLRY rose steadily on news flow: a US Drug Enforcement Administration import authorization for a clinical trial ^[6], a distribution deal with Sandoz Canada, and rising anticipation of Canadian legalization on October 17, 2018.

The blow-off came on September 19, 2018. Shares opened around $233, traded as high as $300 intraday, triggered multiple Nasdaq volatility halts, and closed at $214.06 — a one-day gain of roughly 38% and a market capitalization of about $20 billion, briefly exceeding the market caps of American Airlines, CBS, and Clorox at the time ^[7][8]. The company had reported approximately US$20 million in revenue and a net loss for 2017 ^[1].

Analysts and reporters attributed the move to a textbook short squeeze. Borrow fees on TLRY had climbed to triple-digit annualized rates, the float was tiny, and US investors looking for cannabis exposure had few alternatives on major exchanges ^[7][9]. Tilray CEO Brendan Kennedy appeared on CNBC during the run, and the stock began falling almost immediately after; by year-end 2018 it traded near $70, and by the time Privateer's lockup-related shares were distributed in 2019 the price had fallen further ^[9].

After the bubble: dilution, mergers, and reverse split

Tilray never recaptured its 2018 highs. Key milestones:

• January 2019: 180-day lockup expired; Privateer's shares began their path to public market.
• December 2020: Tilray and Aphria announced an all-stock merger; it closed on May 3, 2021, with the combined company retaining the Tilray name and TLRY ticker, and Aphria CEO Irwin Simon becoming chairman and CEO ^[10].
• September 2023: Tilray acquired a portfolio of craft beer brands from Anheuser-Busch InBev, repositioning as a 'consumer packaged goods' company with cannabis, beverage alcohol, and wellness segments ^[11].
• Ongoing: Heavy share issuance to fund acquisitions pushed the share count from roughly 93 million at IPO to over 900 million by 2024, and the company has signaled potential reverse splits to maintain Nasdaq listing compliance ^[12].

Brendan Kennedy stepped down as CEO at the time of the Aphria merger. Privateer Holdings was effectively wound down through a 2019 reorganization that distributed its Tilray shares to its investors ^[9].

Myths and misreadings

Several persistent stories about the Tilray IPO are worth correcting:

• 'Tilray was the first cannabis company on a US exchange.' It was the first pure-play cannabis producer to IPO on a major US exchange. Cannabis-adjacent companies (e.g., GW Pharmaceuticals, which made the cannabinoid drug Epidiolex) had been listed on Nasdaq since 2013, and Canadian producers traded OTC in the US earlier ^[4][5]. Strong evidence

• 'The September spike proved investor confidence in cannabis.' Contemporary reporting and academic work on the episode characterize it as a mechanical short squeeze driven by tiny float and high borrow costs, not a fundamental revaluation ^[7][9]. Strong evidence

• 'Tilray made early investors rich.' Privateer Holdings and pre-IPO investors did very well on paper at the peak, but lockup restrictions, share distribution mechanics, and the subsequent decline meant most realized returns were a fraction of the September 2018 mark-to-market ^[9]. Retail investors who bought near the top suffered large losses. Strong evidence

• 'The merger with Aphria was a Tilray acquisition.' Legally Tilray was the surviving entity and kept the name and ticker, but Aphria shareholders received approximately 62% of the combined company and Aphria's CEO ran it — most analysts describe it as a reverse merger in substance ^[10]. Strong evidence

Sources

How this page was made